Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$102.3 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 57.27% year-over-year to -$102.3 million in Q1 2026; TTM through Mar 2026 was -$392.5 million, a 56.11% decrease from a year earlier, with the FY2025 full-year figure at -$355.3 million, down 51.61% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$102.3 million, up from -$114.6 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for XENE reached as high as -$19.4 million in Q1 2022 and fell as low as -$114.6 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$58.8 million across 5 years, with a median of -$48.5 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders slumped 146.3% in 2022 and fell 14.87% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$37.4 million in 2022, then dropped by 19.7% to -$44.7 million in 2023, then tumbled by 46.81% to -$65.7 million in 2024, then slumped by 74.51% to -$114.6 million in 2025, then rose by 10.75% to -$102.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$102.3 million in Q1 2026, -$114.6 million in Q4 2025, and -$90.9 million in Q3 2025.